Voyager Therapeutics, Inc.
VYGRNasdaq
$3.17
↑ +4.3%Jul 17 close · end-of-day
Price
1Y↓ -3.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$188.6M
Enterprise Value
$47.1M
P/E
—
P/S
5.2
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
-68.9%
Dividend Yield
—
Revenue (TTM)
$36.5M
Net Income (TTM)
-$116.6M
Free Cash Flow (TTM)
-$129.9M
Gross Margin
—
Operating Margin
-349.2%
Net Margin
-319.6%
ROE
-67.2%
ROIC
-312.7%
Debt / Equity
—
Net Cash
$141.5M
Return 1Y
-1.6%
Company profile
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease.
- CEO
- Alfred W. Sandrock
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Massachusetts
- Website
- voyagertherapeutics.com
Management & directors
- Sandrock AlfredPresident and CEO
- Shiferman Gregory L.SVP and General Counsel
- Carter Todd AlfredChief Scientific Officer
- Jorgensen Nathan D.Chief Financial Officer
- Swartz RobinCOO & CBO
- Ferguson TobyChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
VYGR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.6M↓ -59.9%
Diluted EPS-$0.47↓ -11.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $171.1M | $37.4M | $40.9M | $250.0M | $80.0M | $40.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $27.4M | -$73.6M | -$50.8M | $122.0M | -$83.3M | -$131.8M |
| Net income | $36.7M | -$71.2M | -$46.4M | $132.3M | -$65.0M | -$119.7M |
| Diluted EPS | $0.98 | -$1.89 | -$1.21 | $2.97 | -$1.13 | -$2.04 |
| Operating cash flow | -$96.7M | -$53.5M | -$12.5M | $77.9M | -$15.3M | -$132.5M |
| Free cash flow | -$108.8M | -$55.1M | -$15.0M | $74.7M | -$18.8M | -$135.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 16.0% | -196.8% | -124.3% | 48.8% | -104.1% | -326.6% |
| Net margin | 21.5% | -190.3% | -113.4% | 52.9% | -81.3% | -296.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.6M | $24.6M | $6.3M | $6.5M | $5.2M | $13.4M | $15.3M | $2.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.0M | -$13.8M | -$38.3M | -$34.7M | -$36.6M | -$30.6M | -$29.9M | -$30.3M |
| Net income | -$10.1M | -$9.0M | -$34.5M | -$31.0M | -$33.4M | -$27.9M | -$27.4M | -$27.9M |
| Diluted EPS | -$0.18 | -$0.16 | -$0.59 | -$0.53 | -$0.57 | -$0.47 | -$0.47 | -$0.47 |
| Operating cash flow | -$31.6M | -$28.0M | -$14.5M | -$37.9M | -$33.3M | -$31.0M | -$30.3M | -$33.4M |
| Free cash flow | -$32.5M | -$28.2M | -$14.7M | -$38.6M | -$34.4M | -$31.3M | -$30.9M | -$33.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -50.8% | -56.0% | -610.1% | -536.0% | -704.3% | -228.9% | -195.2% | -1167.4% |
| Net margin | -34.3% | -36.7% | -549.3% | -479.2% | -642.0% | -208.7% | -178.8% | -1077.4% |
Company news
Jul 13, 2026
Jul 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-02 | Sandrock Alfred· President and CEO | Sale | 11,511 | $3.87 | $44,547.57 | filing |
| 2026-04-01 | Shiferman Gregory L.· SVP and General Counsel | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-02-24 | Sandrock Alfred· President and CEO | Sale | 14,197 | $3.79 | $53,806.63 | filing |
| 2026-02-24 | Swartz Robin· COO & CBO | Sale | 6,458 | $3.77 | $24,346.66 | filing |
| 2026-02-24 | Jorgensen Nathan D.· Chief Financial Officer | Sale | 4,668 | $3.77 | $17,598.36 | filing |
| 2026-02-24 | Carter Todd Alfred· Chief Scientific Officer | Sale | 4,174 | $3.76 | $15,694.24 | filing |
| 2026-02-18 | Sandrock Alfred· President and CEO | Sale | 11,732 | $3.41 | $40,006.12 | filing |
| 2026-02-18 | Swartz Robin· COO & CBO | Sale | 3,882 | $3.44 | $13,354.08 | filing |
| 2026-02-18 | Carter Todd Alfred· Chief Scientific Officer | Sale | 3,301 | $3.44 | $11,355.44 | filing |
| 2026-02-10 | Sandrock Alfred· President and CEO | Sale | 12,192 | $3.78 | $46,085.76 | filing |
| 2026-02-10 | Swartz Robin· COO & CBO | Sale | 4,569 | $3.85 | $17,590.65 | filing |
| 2026-02-10 | Carter Todd Alfred· Chief Scientific Officer | Sale | 3,525 | $3.85 | $13,571.25 | filing |
| 2026-02-06 | Ferguson Toby· Chief Medical Officer | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-06 | Carter Todd Alfred· Chief Scientific Officer | Award | 33,000 | $0.00 | $0.00 | filing |
| 2026-02-06 | Swartz Robin· COO & CBO | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-02-06 | Sandrock Alfred· President and CEO | Award | 86,250 | $0.00 | $0.00 | filing |
| 2026-02-06 | Jorgensen Nathan D.· Chief Financial Officer | Award | 32,250 | $0.00 | $0.00 | filing |
| 2025-10-03 | Jorgensen Nathan D.· Chief Financial Officer | Sale | 7,666 | $4.78 | $36,643.48 | filing |
| 2025-08-18 | Ferguson Toby· Chief Medical Officer | Sale | 19,000 | $3.73 | $70,870.00 | filing |
Latest 19 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.